Anna Lembke
Stanford University School of Medicine
Anna Lembke is a Professor of Psychiatry at the Stanford University School of Medicine and chief of the Stanford Addiction Medicine Dual Diagnosis Clinic. Her work centers on addiction medicine, psychiatry, and dopamine-related behaviors, and she is the author of 'Dopamine Nation: Finding Balance in the Age of Indulgence'. Her published research focuses on substance use disorders, examining treatments for opioid and alcohol dependence, associated cardiovascular risks, and the use of machine learning and social media data to monitor addiction trends.
40 claims checked on air: 3 context 1 contradicted 2 overstated 29 supported 5 unverified 3 flagged
What they said on air
Rats genetically engineered to lack dopamine will consume food placed directly in their mouth, but will starve to death if food is placed even a body length away.
"There's a very famous experiment in which rats were engineered to have no dopamine, and the scientists discovered that if they put food in the rat's mouth, the rat would eat, but if you put the food even a body length away, the rat will starve to death" (said at 0:00:00)
The speaker accurately describes the classic findings from rodent models of dopamine deficiency (first genetically developed in mice by Zhou and Palmiter in 1995, and chemically modeled via 6-OHDA neurotoxic lesions in rats). Genetically engineered dopamine-deficient mice lack the motivation to seek food, exhibiting severe aphagia and adipsia that leads to starvation unless rescued (e.g., with L-DOPA injections), yet they retain normal hedonic responses (taste reactivity) and will ingest food or sucrose solutions delivered directly to their mouths. Because the evidence comes from mechanistic animal models, the GRADE certainty is very low.
- supports: Cre recombinase-mediated restoration of nigrostriatal dopamine in dopamine-deficient mice … (Proceedings of the National Academy of Sciences of the United States of America 2006) · cited 213x in the literature
"DDfs mice have trace brain dopamine content, severe hypoactivity, and aphagia, and they die without intervention. However, they can be maintained by daily treatment with l-3,4-dihydroxyphenylalanine (L-dopa)." (abstract, passage verified)
pubmedfull study (doi) - supports: Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. (Cell 1995) · cited 741x in the literature
"These DA-deficient (DA-/-) mice were born at expected frequency but became hypoactive and stopped feeding a few weeks after birth... Within a few minutes of being injected with L-dihdroxyphenylalanine (L-DOPA), the product of TH, the DA-/- mice became more active and consumed more food than control mice." (abstract)
pubmedfull study (doi)
The genetic risk of developing an addiction is approximately 50% to 60%.
"the genetic risk of addiction is about 50 to 60%. So if you have a biological parent or grandparent with addiction, you are more likely to develop that addiction." (said at 0:00:27)
No published record matching the claim that the genetic risk of developing an addiction is approximately 50% to 60% was located; this does not prove the claim false.
The brain processes pleasure and pain within the same anatomical neural regions.
"One of the most important findings in neuroscience in the past 75 years is that the same parts of the brain that process pleasure also process pain" (said at 0:00:54)
Extensive neuroimaging and neurobiological evidence confirms that pleasure and pain share overlapping anatomical substrates and neurochemical systems within the brain. Key structures including the nucleus accumbens, anterior cingulate cortex, insular cortex, amygdala, prefrontal cortex, and periaqueductal gray are involved in processing both painful and rewarding/pleasant stimuli, largely mediated by common dopaminergic and opioid pathways.
Parkinson's disease is caused by dopamine depletion in the substantia nigra region of the brain.
"Parkinson's disease, which is a disease related to stiffness and tremor, is caused by a depletion of dopamine in a part of the brain called the substantia nigra. And as dopamine gets depleted in that part of the brain, people lose the ability to move their bodies." (said at 0:08:23)
The speaker's statement accurately reflects the established pathophysiology of Parkinson's disease. Parkinson's disease is a progressive neurodegenerative movement disorder characterized by cardinal motor symptoms including rigidity (stiffness), resting tremor, and bradykinesia (impaired/slowed movement). Its primary neuropathological hallmark is the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, resulting in striatal dopamine depletion and subsequent dysfunction in motor control circuits.
- supports: Parkinson's disease: pathogenesis and therapeutic strategies. (Molecular biomedicine 2026) · cited 9x in the literature
"Parkinson's disease (PD) is a neurodegenerative disorder primarily characterized by motor impairments such as bradykinesia, tremor, and rigidity. Its neuropathological hallmarks include the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the aggregation of α-synuclein (α-syn) into Lewy bodies (LBs)" (abstract, background, passage verified)
pubmedfull study (doi) - supports: Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obsta… (NeuroSci 2026)
"Parkinson's disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons. Its symptoms affect both motor functions-such as bradykinesia, rigidity, resting tremor, and postural instability-and non-motor functions" (abstract, background, passage verified)
pubmedfull study (doi)
Addiction leads to disconnection or severing of large neuronal pathways between deep limbic structures (like the nucleus accumbens and ventral tegmental area) and the prefrontal cortex.
"What we're finding is that there's actually a disconnect. So there are large neuronal circuits and pathways between those deep limbic structures and the prefrontal cortex that literally get severed or disconnected when people become addicted." (said at 0:11:41)
Substance use disorders and addiction are widely documented to involve altered functional connectivity and reduced white matter microstructural integrity within frontostriatal and corticolimbic circuits connecting the prefrontal cortex to deep structures such as the nucleus accumbens. However, claiming that these neuronal pathways "literally get severed" exaggerates the nature of these neurobiological changes. The pathways remain anatomically present; addiction is characterized by changes in synaptic plasticity, functional coupling, and microstructural metrics (such as reduced fractional anisotropy on diffusion tensor imaging), rather than literal physical transection or severing of nerve tracts.
- partial: Emerging role for the medial prefrontal cortex in alcohol-seeking behaviors. (Addictive behaviors 2018) · cited 62x in the literature
"The medial prefrontal cortex (mPFC) plays an important role in high-order executive processes and sends highly organized projections to sub-cortical regions controlling mood, motivation and impulsivity." (abstract, introduction, passage verified)
pubmedfull study (doi) - partial: Brain tract structure predicts relapse to stimulant drug use. (Proceedings of the National Academy of Sciences of the United States of America 2022) · cited 25x in the literature
"reduced diffusion metrics of a tract projecting from the right anterior insula to the NAcc were associated with subsequent relapse to stimulant use, but not with previous diagnosis." (abstract, results, passage verified)
pubmedfull study (doi) - partial: Nucleus accumbens: a systematic review of neural circuitry and clinical studies in healthy… (Journal of neurosurgery 2023) · cited 39x in the literature
"The NAcc and its corticolimbic connections to other brain regions, such as the prefrontal cortex, are largely involved in reward and pain processes, with distinct functional circuitry between the shell and core in healthy patients." (abstract, results, passage verified)
pubmedfull study (doi)
Alcohol acts through endogenous opioid and GABA receptor systems to stimulate dopamine release in the reward pathway.
"alcohol works through its own chemical pathway. It works on our endogenous opioid system, the opioids that we make—we have receptors for opioids in our brains. It works on our endogenous GABA system, which is our calming neurotransmitter. And at the end of the day, it releases dopamine in the reward pathway." (said at 0:12:25)
The statement accurately reflects established neurobiological mechanisms of ethanol action. Alcohol exerts primary pharmacological actions on GABAergic systems (facilitating inhibitory/calming neurotransmission and disinhibitory circuits in the ventral tegmental area) and engages the endogenous opioid system. Pharmacological studies demonstrate that ethanol-induced activation of mu-opioid receptors and modulation of GABAergic transmission directly stimulate dopamine release within the mesolimbic reward pathway.
In response to elevated dopamine transmission, the brain downregulates signaling by internalizing (involuting) postsynaptic dopamine receptors.
"our brain will try to compensate or adapt to increased dopamine firing by downregulating dopamine transmission, for example, by involuting postsynaptic dopamine receptors." (said at 0:15:48)
Postsynaptic dopamine receptors belong to the G protein-coupled receptor (GPCR) superfamily. In response to sustained or elevated agonist activation (such as increased dopamine firing), GPCRs canonically undergo homologous desensitization, arrestin recruitment, and endocytic internalization (involuntary removal from the cell surface), which downregulates downstream signaling.
The universal symptoms of withdrawal from any addictive substance or behavior are anxiety, irritability, insomnia, depression, and craving.
"experiencing the universal symptoms of withdrawal from any addictive substance or behavior, which are anxiety, irritability, insomnia, depression, and craving." (said at 0:23:47)
Neurobiological models of addiction characterize the withdrawal/negative affect stage across addictive substances and behavioral addictions by a common motivational withdrawal syndrome. This state is marked by negative emotional symptoms including anxiety, irritability, dysphoria or depression, craving, and sleep disturbances. However, labeling these exact five symptoms as universal across every addiction requires qualification: physical and acute withdrawal profiles vary markedly depending on the substance (for example, acute stimulant withdrawal is typically characterized by hypersomnia rather than insomnia, whereas sedative-hypnotic and opioid withdrawal produce pronounced autonomic and somatic symptoms).
Individuals with co-occurring psychiatric disorders are at an increased risk of developing addiction.
"And we know that people with co-occurring psychiatric disorders, for example, are at increased risk of developing addiction, probably because they're reaching for that substance to self-medicate their psychiatric problem." (said at 0:26:38)
Large-scale epidemiological studies, such as the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; N=43,093), demonstrate strong, statistically significant associations between independent psychiatric conditions (including mood, anxiety, and personality disorders) and the risk of developing substance abuse and dependence.
Laboratory rodents provided with self-administered cocaine will repeatedly press a lever for the drug until reaching exhaustion or death.
"first of all, rodents very easily get addicted to cocaine. They will press a lever for cocaine until exhaustion or death." (said at 0:29:17)
Laboratory animal studies demonstrate that when rats are given continuous, unlimited access to intravenous cocaine via lever pressing, they engage in severe episodic binges of drug self-administration alternating with brief periods of abstinence. Under these continuous-access conditions, the animals show severe physical deterioration, cessation of normal grooming, substantial weight loss (up to 47%), and high mortality (a 90% mortality rate within 30 days). Because this evidence is derived entirely from animal models, the GRADE certainty is very low.
- supports: Toxicity associated with long-term intravenous heroin and cocaine self-administration in t… (JAMA 1985) · cited 261x in the literature
"Animals self-administering cocaine quickly developed a pattern of episodic drug intake, with periods of excessive cocaine self-administration alternating with brief periods of abstinence... rats self-administering cocaine tended to cease grooming behavior, to lose up to 47% of their pretesting body weight, and to show a pronounced deterioration in general health. The mortality rate for 30 days of continuous testing was 36% for animals self-administering heroin and 90% for those self-administering cocaine." (abstract, results)
pubmed
In rodent experiments where cocaine self-administration has been extinguished, applying a severe physical stressor such as a painful foot shock causes the rodent to immediately resume lever-pressing for cocaine.
"if that cocaine is then taken away, that behavior will extinguish, which means that the mice will eventually just stop pressing the lever, right? Because they're not getting any cocaine... But if they're then exposed to a very painful foot shock, right? So a very extreme physical pain, which you could equate to a serious life stressor, the first thing the rat will do is run over to the lever and start pressing for cocaine" (said at 0:29:22)
Extensive preclinical literature establishes that in rodents trained to self-administer cocaine whose drug-seeking behavior has undergone extinction, exposure to an acute physical stressor—most commonly intermittent electric footshock—reliably reinstates lever-pressing behavior previously associated with drug delivery (the stress-induced reinstatement model of relapse). As this evidence is derived from animal models, the GRADE certainty is rated as very low.
- supports: Prime-, stress-, and cue-induced reinstatement of extinguished drug-reinforced responding … (Current protocols in neuroscience 2012) · cited 14x in the literature
"This unit describes the testing of rats in prime-, footshock-, and cue-induced reinstatement procedures. Evaluating rats in these procedures enables the assessment of treatments on behavior thought to model drug relapse precipitated by re-contact with an abused drug (prime-induced), induced by stress (footshock-induced), or by stimuli previously associated with drug administration (cue-induced)." (abstract, passage verified)
pubmedfull study (doi) - supports: Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free peri… (Psychopharmacology 1996) · cited 406x in the literature
"Here we report that in rats trained to self-administer cocaine, exposure to acute intermittent footshock stress induces reinstatement of cocaine-taking behavior after prolonged extinction sessions and after a 4- to 6-week drug-free period; an effect comparable to that induced by a priming injection of cocaine." (abstract, results, passage verified)
pubmedfull study (doi)
Consuming excessive amounts of water can cause hyponatremia that leads to delirium.
"she discovered that by drinking copious amounts of water, she could become hyponatremic, meaning that she could lower the sodium levels in her bloodstream, which would then lead her to become delirious." (said at 0:32:10)
Consuming excessive amounts of water (such as in psychogenic polydipsia or water intoxication) can overwhelm renal excretory capacity and cause dilutional hyponatremia (a fall in serum sodium levels). Acute or severe hyponatremia leads to cerebral edema and acute metabolic encephalopathy, manifesting clinically as delirium, altered mental status, seizures, coma, or death.
There are no biological measurements, brain scans, or blood tests to clinically diagnose addiction.
"And you know, if and when it tips over into what we would call addiction, there's not a brain scan or a blood test to assess that. It's not like switching a light switch and it's like, "Oh yeah, now you have addiction." It's not like that. It's often a gradual and insidious thing. And we don't, in fact, have a biological measurement of addiction; we base it on what we call phenomenology, which is patterns of behavior that repeat themselves across time." (said at 0:35:10)
The speaker's assertion is correct. Diagnostic frameworks for substance use disorders and addiction (such as the DSM-5) rely on clinical phenomenology and behavioral criteria (e.g., impaired control, social impairment, risky use, and pharmacological criteria) rather than objective biological tests. While candidate neuroimaging markers (neuromarkers) and peripheral biomarkers are being actively researched, there are currently no clinically validated brain scans or blood tests used to diagnose addiction in routine clinical practice.
Recent medical literature confirms that although neuroimaging and molecular markers for addiction are under development to better understand the neurobiological basis of substance use disorders, clinical diagnosis remains strictly based on behavioral assessments and patient-reported symptoms (PMID: 38630190, PMID: 35040765).
Addiction is defined clinically as the continued, compulsive use of a substance or behavior despite harm to self or others.
"And broadly speaking, the definition of addiction is the continued, compulsive use of a substance or a behavior despite harm to self and/or others." (said at 0:35:46)
The speaker's definition aligns with major clinical and diagnostic consensus definitions of addiction (including those from the American Society of Addiction Medicine [ASAM], the National Institute on Drug Abuse [NIDA], the DSM-5, and ICD-11). Addiction is standardly characterized as a chronic condition involving compulsive substance use or behavioral engagement despite negative, harmful consequences to health, functioning, or social relationships.
- supports: The process addictions and the new ASAM definition of addiction. (Journal of psychoactive drugs 2012) · cited 147x in the literature
"Addiction is a primary, chronic disease involving brain reward, motivation, memory and related circuitry; it can lead to relapse, progressive development, and the potential for fatality if not treated. While pathological use of alcohol and, more recently, psychoactive substances have been accepted as addictive diseases, developing brain science has set the stage for inclusion of the process addictions, including food, sex, shopping and gambling problems, in a broader definition of addiction as set forth by the American Society of Addiction Medicine in 2011." (abstract, description of ASAM definition, passage verified)
pubmedfull study (doi)
Digital media engages the same brain reward pathways as drugs and alcohol.
"There's no doubt that digital media lights up the same reward pathway as drugs and alcohol." (said at 0:42:10)
The claim is supported by neuroimaging and addiction research. Drugs of abuse and alcohol drive reinforcement through the mesolimbic reward pathway, centered on the ventral tegmental area, nucleus accumbens (NAcc), and prefrontal cortex. Functional neuroimaging studies and systematic reviews consistently demonstrate that digital and social media stimuli—such as receiving "likes," peer approval, or reputational gains—activate this same mesolimbic reward circuitry, particularly the nucleus accumbens and ventral striatum.
- supports: Peer Influence Via Instagram: Effects on Brain and Behavior in Adolescence and Young Adult… (Child development 2018) · cited 205x in the literature
"Popular photographs elicited greater activity in multiple brain regions, including the nucleus accumbens (NAcc), a hub of the brain's reward circuitry." (abstract, passage verified)
pubmedfull study (doi) - supports: The Effects of Social Feedback Through the "Like" Feature on Brain Activity: A Systematic … (Healthcare (Basel, Switzerland) 2025) · cited 14x in the literature
"The review included 11 studies with 504 participants, identifying key brain structures such as the amygdala, ventromedial prefrontal cortex (vmPFC), and ventral striatum involved in reward processing. Positive feedback ("likes") activates areas like the nucleus accumbens (NACC), vmPFC, and amygdala, with NACC correlating with increased SM use intensity." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Addiction and stress: Exploring the reward pathways in brain affected by different drugs. (Progress in brain research 2025) · cited 5x in the literature
"The reinforcement of addictive behaviors is mostly dependent on the brain's reward circuits, which include the nucleus accumbens, ventral tegmental region, and prefrontal cortex, in addition to neurotransmitters such as dopamine, serotonin, and endorphins." (abstract, passage verified)
pubmedfull study (doi)
Acute withdrawal from an addictive substance or behavior typically lasts 10 to 14 days.
"and that lasted a good 10 to 14 days, completely mapping on with the amount of time it takes typically to get out of acute withdrawal." (said at 0:44:25)
No published record matching the claim that acute withdrawal from an addictive substance or behavior typically lasts 10 to 14 days was located; this does not prove the claim false.
The average lifespan of a business is currently around 15 years, compared to 50 years approximately 50 years ago.
"I I recently read that the the average life of a business now is like 15 years, whereas, you know, 50 years ago it was 50 years." (said at 0:52:24)
The statement reflects findings widely cited from corporate longevity studies conducted by consultancy firms such as Innosight and researchers like Richard Foster. These analyses examine the average tenure (or rolling average lifespan) of companies listed on the S&P 500 index, showing that average tenure dropped from roughly 50–60 years in the 1950s/1960s to under 20 years (around 15 to 18 years) in recent decades. However, qualifying context is necessary: this statistic measures the duration a large corporation remains on a specific stock market index (the S&P 500) prior to being removed due to mergers, acquisitions, or market cap changes, rather than the true operational lifespan or bankruptcy of all businesses in general (the vast majority of which are small enterprises with average lifespans under 10 years).
Doctors and lawyers experience rates of alcoholism equal to those in blue-collar occupations.
"You know, maybe that's partially true, but even people doing, like doctors and lawyers, they are— HOST: Oh, okay. Yeah. GUEST1: Equal rates of alcoholism among those groups." (said at 0:53:46)
No published record matching the claim that doctors and lawyers experience rates of alcoholism equal to those in blue-collar occupations was located; this does not prove the claim false.
Absolute dopamine concentrations can be measured directly in rodent brains, whereas in living humans researchers are limited to relative measurements of dopamine transmission.
"we don't really have good ways of measuring absolute values of dopamine in human beings, right? We can do that in rats, but we can't really do that in humans. It's relative values." (said at 0:55:45)
In rodent models, invasive methodologies such as in vivo cerebral microdialysis, fast-scan cyclic voltammetry, and tissue high-performance liquid chromatography permit direct quantification of absolute extracellular or tissue dopamine concentrations (e.g., in nanomolar units or picograms per milligram of tissue). In contrast, neurochemical assessments in living human brains primarily rely on non-invasive molecular neuroimaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT). These imaging paradigms measure relative changes in radioligand binding potential or receptor displacement (competition with endogenous dopamine at D2/D3 receptors) following pharmacological or behavioral challenges, rather than quantifying absolute baseline molar concentrations.
Brain scans of individuals addicted to cocaine, methamphetamine, alcohol, or heroin show persistent dopamine transmission deficits two weeks after cessation of use.
"And importantly, these individuals who are addicted to these substances, these brain scans were done two weeks after they stopped using. HOST: Oh, wow. GUEST1: Yeah. Which tells us that this dopamine deficit state persists for some period of time." (said at 0:57:30)
Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging studies consistently demonstrate striatal dopamine deficits in substance-dependent individuals during early abstinence (typically measured around 1 to 3 weeks, or approximately two weeks, after last use). A systematic review and meta-analysis of 31 imaging studies found marked reductions in striatal dopamine release (effect size -0.84), dopamine transporter availability (effect size -0.91), and dopamine D2/D3 receptor availability (effect size -0.76) across stimulant users evaluated after 5 days to 3 weeks of abstinence compared to healthy controls.
- supports: Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamin… (JAMA psychiatry 2017) · cited 332x in the literature
"A total of 31 studies that compared dopaminergic measures between 519 stimulant users and 512 healthy controls were included in the final analysis. In most of the studies, the duration of abstinence varied from 5 days to 3 weeks. There was a significant decrease in striatal dopamine release in stimulant users compared with healthy controls: the effect size was -0.84 (95% CI, -1.08 to -0.60; P < .001) for stimulants combined and -0.87 (95% CI, -1.15 to -0.60; P < .001) for cocaine. In addition, there was a significant decrease in dopamine transporter availability... There was also a significant decrease in D2/D3 receptor availability: the effect size was -0.76 (95% CI, -0.92 to -0.60; P < .001)..." (abstract, results, passage verified)
pubmedfull study (doi)
Parkinson's disease motor symptoms are caused by the depletion of dopamine in the substantia nigra.
"people with Parkinson's have depletion of dopamine in the substantia nigra. That's what causes that motor disease." (said at 0:59:20)
Parkinson's disease is well established to be characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. This loss results in dopamine depletion across the nigrostriatal pathway, which leads to the cardinal motor symptoms of the disorder, including bradykinesia, rigidity, and resting tremor.
Pure dopamine cannot cross the blood-brain barrier when ingested or administered peripherally, whereas L-DOPA does cross the blood-brain barrier.
"If I were to give you a spoonful of dopamine, it would do absolutely nothing because it doesn't cross into the brain. It doesn't cross the blood-brain barrier. But I could give you L-DOPA, which is a precursor chemical that would cross your blood-brain barrier and get turned into dopamine" (said at 0:59:28)
The speaker's statement accurately reflects established neuropharmacology. Peripheral dopamine does not cross the digestive tract or the blood-brain barrier (BBB) to produce central nervous system effects. In contrast, its precursor L-DOPA (levodopa) is an amino acid that readily crosses the blood-brain barrier via large neutral amino acid transporters, where it is subsequently converted into dopamine by aromatic L-amino acid decarboxylase.
- supports: Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related comp… (Nature medicine 2025) · cited 15x in the literature
"Dopamine does not cross the digestive and blood-brain barriers and is rapidly oxidized." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The role of L-DOPA in neurological and neurodegenerative complications: a review. (Molecular and cellular biochemistry 2025) · cited 5x in the literature
"As a direct precursor to dopamine, L-DOPA is synthesized from L-tyrosine through the action of tyrosine hydroxylase and is subsequently converted into dopamine via aromatic L-amino acid decarboxylase. Its ability to cross the blood-brain barrier (BBB) makes it a crucial therapeutic agent for restoring dopaminergic neurotransmission, thereby influencing motor function, cognition, and neuroprotection." (abstract, background, passage verified)
pubmedfull study (doi) - supports: A novel nanocomposite Lf-DA-MSN-PF127 aided the delivery of dopamine for the treatment of … (Nanoscale advances 2025) · cited 4x in the literature
"Levodopa is a prescribed medicine for symptomatic relief of PD, as it is an amino acid precursor of dopamine that readily crosses the Blood-Brain Barrier (BBB)." (abstract, background, passage verified)
pubmedfull study (doi)
Approximately 1 in 4 Parkinson's disease patients receiving dopamine replacement therapy develop a de novo addictive or impulse control disorder.
"When we give patients with Parkinson's dopamine in this form, that can temporarily improve their movements, but in about one in four Parkinson's patients, they will develop a de novo addictive disorder: shopping addiction, sex addiction, other types of addiction" (said at 0:59:45)
The claim that approximately 1 in 4 (25%) Parkinson's disease patients receiving dopamine replacement therapy develop impulse control disorders (such as compulsive shopping, hypersexuality, or gambling) is well-aligned with published clinical research. Large cross-sectional studies demonstrate point prevalence rates of 13.6% overall and 17.1% specifically among patients treated with dopamine agonists. Longitudinal studies following patients over 5 years demonstrate an even higher 5-year cumulative incidence of 46.1% (and 51.5% among dopamine agonist users), with overall prevalence reaching 32.8% at 5 years.
- supports: Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. (Archives of neurology 2010) · cited 1476x in the literature
"An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs. Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P < .001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Longitudinal analysis of impulse control disorders in Parkinson disease. (Neurology 2018) · cited 252x in the literature
"In 306 patients without ICDs at baseline, the 5-year cumulative incidence of ICDs was 46.1% (95% confidence interval [CI] 37.4-55.7, DA ever users 51.5% [95% CI 41.8-62.1], DA never users 12.4% [95% CI 4.8-30.0]). ICD prevalence increased from 19.7% at baseline to 32.8% after 5 years." (abstract, results, passage verified)
pubmedfull study (doi)
Human studies demonstrate that dopamine levels gradually rise during the latter half of exercise and remain elevated for hours afterwards before returning to baseline without entering a dopamine deficit state.
"And there are studies in humans showing that when humans expose themselves to exercise, for example, dopamine levels gradually rise over the latter half of the exercise, and then when the exercise stops, dopamine levels will remain elevated for hours afterwards before going back down to the baseline level position without ever going into that dopamine deficit state." (said at 1:02:04)
While human neuroimaging studies using positron emission tomography (PET) with tracers like [11C]raclopride demonstrate that acute exercise stimulates endogenous dopamine release in the human brain, they do not show the continuous kinetic profile described by the speaker. PET provides static snapshots of receptor binding displacement across discrete scan conditions rather than continuous dynamic tracking across the phases of an exercise session. The specific temporal kinetics claimed—gradual elevation during the latter half of exertion and sustained elevation for hours post-exercise without entering a deficit state—derive from invasive intracerebral microdialysis studies in rodents, not in humans.
A 14-year-old boy became addicted to an AI chatbot and committed suicide to join the imaginary persona, a case documented in major news outlets.
"I mean, there was just this tragic case of a young man who essentially got addicted to a chatbot—I think he was 14, not my patient, it was written up um in the New York Times, in the Wall Street Journal—and he fell in love with this chatbot, started to isolate, wasn't spending time with his family or friends, and then eventually took his own life purportedly so he could join this imaginary person." (said at 1:06:35)
The claim accurately describes a widely publicized case of a 14-year-old boy (Sewell Setzer III) who developed an emotional dependence on an artificial intelligence chatbot (on the Character.AI platform) and committed suicide in 2024. The case was reported in major news outlets including *The New York Times* ("Can A.I. Be Primary Companion? For One Teen, It Was Fatal") and *The Wall Street Journal*, and subsequently analyzed in peer-reviewed legal/medical literature (Marchetti et al., 2026, PMID 42340762). Per standard grading guidelines, because the evidence for this specific event comes from case reports and legal filings rather than clinical trials or observational cohort studies, the certainty of evidence for this individual case design is very low.
The organ damaged the most by cannabis is the brain.
"The target organ that it damages the most is the brain." (said at 1:07:14)
No published record matching the claim that the brain is the organ damaged the most by cannabis was located; this does not prove the claim false.
Chronic cannabis exposure can lead to cannabinoid hyperemesis syndrome, causing cyclical vomiting despite initial anti-emetic effects.
"Plus we often see something called the hyperemesis syndrome. So cannabis can help with nausea and vomiting; it can help decrease the feeling of wanting to vomit. But again, as the brain continues to be exposed to it, there's this process of neuroadaptation. It stops working, and it can even turn on them and do the opposite. So eventually people can actually have a cyclical vomiting syndrome as a result of cannabis." (said at 1:07:46)
Published medical literature and clinical reviews confirm that while cannabinoids have established anti-emetic properties at low doses, chronic and heavy cannabis exposure can induce cannabinoid hyperemesis syndrome (CHS). CHS is characterized by recurrent, cyclical episodes of severe nausea and intractable vomiting. The pathophysiological framework involves dysregulation and neuroadaptation of the endocannabinoid system and cannabinoid type 1 (CB1) receptors along the gut-brain axis, transitioning from anti-emetic effects to paradoxical pro-emetic effects with prolonged, high-dose exposure. Symptoms typically resolve with sustained cannabis cessation.
Cessation of cannabis use causes withdrawal characterized primarily by psychological symptoms including anxiety, irritability, depression, insomnia, and craving.
"the universal symptoms of addiction are psychological symptoms: anxiety, irritability, depression, insomnia, craving. And people have that in spades when they try to stop using cannabis." (said at 1:18:00)
Cannabis withdrawal syndrome is a well-established clinical diagnosis included in the DSM-5 and ICD-11. Systematic reviews, epidemiological data (such as the NESARC-III survey of frequent cannabis users), and controlled residential abstinence studies confirm that cessation among regular cannabis users reliably induces withdrawal characterized predominantly by psychological and behavioral symptoms, including anxiety/nervousness, irritability/hostility, depressed mood, insomnia/sleep disruption, and craving.
- supports: Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence with… (The American journal on addictions 2014) · cited 66x in the literature
"Most abstinence effects, including irritability and anxiety were greatest on Days 0-3 and decreased thereafter. Cannabis craving significantly decreased over time, whereas decreased appetite began to normalize on Day 4." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The cannabis withdrawal syndrome: current insights. (Substance abuse and rehabilitation 2017) · cited 224x in the literature
"Several lines of evidence from animal and human studies indicate that cessation from long-term and regular cannabis use precipitates a specific withdrawal syndrome with mainly mood and behavioral symptoms of light to moderate intensity, which can usually be treated in an outpatient setting." (abstract, passage verified)
pubmedfull study (doi) - supports: DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. (Drug and alcohol dependence 2019) · cited 87x in the literature
"The most common withdrawal symptoms among those with CWS were nervousness/anxiety (76.3%), hostility (71.9%), sleep difficulty (68.2%) and depressed mood (58.9%)." (abstract, results, passage verified)
pubmedfull study (doi)
Demographic trends show an increasing proportion of people living alone and having fewer close social contacts.
"keep in mind, too, that more and more people live alone and have maybe fewer close contacts." (said at 1:35:47)
Demographic and social network research confirms both parts of the claim: first, global demographic trends show a substantial increase in single-person households and older adults living alone across many regions (e.g., Esteve et al., 2018; Pynnönen et al., 2018); second, longitudinal population surveys show increases in time spent alone and decreases in close social contacts / face-to-face social interactions over recent decades (e.g., Kauppinen et al., 2020).
- supports: Living Alone in Later Life: A Global Perspective (Population and Development Review 2018) · cited 231x in the literature
"The prevalence of living alone during later life varies widely throughout the world, though everywhere its social relevance has grown substantially in recent decades. This living arrangement, more widespread among women than men aged over 65, is one of the most visible characteristics of societal aging currently underway." (abstract, passage verified)
openalexfull study (doi) - supports: Disconnected Lives: Trends in Time Spent Alone in Finland (Social Indicators Research 2020) · cited 23x in the literature
"Structural factors, such as aging and an increase in the number of single households, are strongly associated with increased time spent alone. Time spent alone has increased, especially during leisure activities. Specifically, time spent watching television and using computers is associated with the decreasing tendency for face-to-face interaction." (abstract, results, passage verified)
openalexfull study (doi)
Sociologist Kai Erikson's study of Puritan societies demonstrated that human groups consistently maintain a stable proportion of members labeled as deviant or pushed to the margins.
"Kai Erikson wrote this book on deviance where he studied Puritan societies and found that no matter what group of humans you looked at, there were always going to be people who were on the margins of the society. He used the word "deviant."" (said at 1:42:14)
The speaker accurately describes sociologist Kai T. Erikson's classical work in the sociology of deviance. In his influential 1966 book 'Wayward Puritans: A Study in the Sociology of Deviance' (elaborating on his 1962 paper 'Notes on the Sociology of Deviance'), Erikson applied Émile Durkheim's functionalist theory to 17th-century Massachusetts Bay Puritans. He argued that deviance serves essential social boundary-defining functions and hypothesized that societies consistently maintain a relatively stable volume/quota of deviance and marginality across changing circumstances.
- supports: Notes on The Sociology of Deviance (? 2018) · cited 8x in the literature
"The following selection sketches the theoretical orientation used in Wayward Puritans (Wiley, 1966), a historical and sociological study of deviance among the Massachusetts Bay Puritans in the 17th century, which won the 1967 Maclver Award of the American Sociological Association. In this book and other articles Erikson has contributed significantly to our knowledge of the processes by which society screens behavior and attributes deviance." (abstract, passage verified)
openalexfull study (doi)
Sex and orgasm stimulate dopamine release within the brain's reward pathway.
"All of this is related to sex and orgasm, which releases dopamine in the reward pathway." (said at 1:46:58)
Preclinical and clinical neurobiological research confirms that sexual behavior and arousal engage the mesolimbic reward pathway, stimulating dopamine release in key regions such as the nucleus accumbens. Extensive microdialysis studies demonstrate sustained elevations in nucleus accumbens dopamine during sexual interaction and copulation, which interact with other neurochemical systems (such as opioids and oxytocin) during climax and reward processing.
- supports: Dopamine, Erectile Function and Male Sexual Behavior from the Past to the Present: A Revie… (Brain sciences 2022) · cited 65x in the literature
"These studies show that (i) the mesolimbic/mesocortical dopaminergic system plays a key role in the preparatory phase of sexual behavior, e.g., in sexual arousal, motivation and reward, whereas the nigrostriatal system controls the sensory-motor coordination necessary for copulation" (abstract, passage verified)
pubmedfull study (doi) - supports: The nucleus accumbens dopamine increase, typically triggered by sexual stimuli in male rat… (Psychopharmacology 2022) · cited 12x in the literature
"Exposure of male rats to an inaccessible receptive female and copulation increases dopamine (DA) levels in the nucleus accumbens (NAcc)." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Orgasms, sexual pleasure, and opioid reward mechanisms. (Sexual medicine reviews 2025) · cited 10x in the literature
"Appetitive sexual pleasure involves the activation of dopamine and oxytocin release in hypothalamic and mesolimbic regions that regulate sexual arousal and desire, and are reinforced by localized opioid activity." (abstract, results, passage verified)
pubmedfull study (doi)
Brain imaging studies show that individuals stopping an addictive substance remain in a dopamine deficit state at two weeks of abstinence.
"We know that from this imaging study, right, that people are still in that dopamine deficit state two weeks after stopping." (said at 1:55:27)
Human brain imaging studies (using PET and SPECT) demonstrate that individuals abstinent from addictive substances—particularly stimulants such as cocaine, methamphetamine, and amphetamine—exhibit substantial down-regulation of both presynaptic and postsynaptic dopaminergic markers during early and intermediate abstinence (typically evaluated between 5 days and 3 to 4 weeks of abstinence, which includes the 2-week timeframe). A comprehensive meta-analysis of 31 imaging studies found marked reductions in striatal dopamine release (effect size -0.84), dopamine transporter availability (-0.91), and dopamine D2/D3 receptor availability (-0.76) in abstinent users compared to controls.
- supports: Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamin… (JAMA psychiatry 2017) · cited 332x in the literature
"A total of 31 studies that compared dopaminergic measures between 519 stimulant users and 512 healthy controls were included in the final analysis. In most of the studies, the duration of abstinence varied from 5 days to 3 weeks. There was a significant decrease in striatal dopamine release in stimulant users compared with healthy controls: the effect size was -0.84 (95% CI, -1.08 to -0.60; P < .001) for stimulants combined and -0.87 (95% CI, -1.15 to -0.60; P < .001) for cocaine. In addition, there was a significant decrease in dopamine transporter availability: the effect size was -0.91 (95% CI, -1.50 to -0.32; P < .01) for stimulants combined... There was also a significant decrease in D2/D3 receptor availability: the effect size was -0.76 (95% CI, -0.92 to -0.60; P < .001)" (abstract, results, passage verified)
pubmedfull study (doi)
Women are substantially more vulnerable to love addiction or pathological relationship dependency than men.
"Women, however, are much more vulnerable to love addiction, which is also real, right? The pathological, compulsive falling in love with partners and then getting into these relationships that are really dramatic and not healthy" (said at 1:57:15)
The claim that women are substantially or "much more vulnerable" to love addiction compared to men is not supported by psychiatric and empirical literature. "Love addiction" is not an officially recognized diagnosis in the DSM-5 or ICD-11, and systematic reviews highlight an absence of standardized epidemiological data. Furthermore, recent empirical studies evaluating psychological vulnerability models (such as impulsivity, psychological distress, and emotion dysregulation) for love addiction show structural invariance across genders, and meta-analytic evidence indicates that associations with key drivers like anxious attachment are not uniquely higher in women (and can be stronger in male-predominant samples).
- contradicts: Is love passion an addictive disorder? (The American journal of drug and alcohol abuse 2010) · cited 140x in the literature
"There are no recognized definitions or diagnostic criteria for "love addiction"... There are no data on the epidemiology, genetics, co-morbidity, or treatment of love addiction." (abstract, results)
pubmedfull study (doi) - contradicts: Problematic Love Behaviors and Correlated Factors: A Systematic Review with Subgroup Meta-… (Archives of sexual behavior 2026) · cited 1x in the literature
"Conversely, the link between LA and anxious attachment was stronger in samples with a higher proportion of men." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Psychological Distress, Motor Impulsivity and Love Addiction: The Mediating Role of Emotio… (Psychological reports 2026)
"multigroup analysis confirmed that the structural model was strictly invariant across genders." (abstract, results, passage verified)
pubmedfull study (doi)
Withdrawal symptoms and intense cravings following sugar cessation typically last for approximately two weeks.
"And when we quit sugar, we have a comedown, right? We go into withdrawal, and it's manifested in all the different ways that we've talked about. And it lasts for about two weeks, and one of the most salient symptoms is intense craving for sugar." (said at 1:58:41)
While scientific literature and clinical studies confirm that attempts to reduce or cease sugar intake can lead to withdrawal-like symptoms—including low energy, depressed mood, body aches, and prominent sugar cravings—there is no fixed or standardized timeline establishing that these symptoms typically last for two weeks across the population. Ecological momentary assessment (EMA) research evaluating symptom trajectories during sugar reduction demonstrates that individuals experience substance-use-disorder-like symptoms (e.g., cravings, preoccupation, fatigue, low mood) during quitting attempts, but symptom burden varies significantly based on individual factors such as baseline sugar intake, food addiction traits, BMI, and psychological distress. Moreover, the construct of sugar addiction itself remains debated in clinical science.
Sugar consumption stimulates dopamine release in the nucleus accumbens, activating the same reward pathway as drugs of abuse and alcohol.
"sugar is addictive. It lights up the same reward pathway as drugs and alcohol. Clear dopamine release in the nucleus accumbens part of the reward pathway in response to sugar." (said at 1:58:42)
Preclinical studies and neurobiological reviews demonstrate that sucrose consumption stimulates extracellular dopamine release in the nucleus accumbens and activates the mesolimbic dopamine and opioid reward systems, which are the same neural pathways engaged by drugs of abuse and alcohol. Animal models show that intermittent access to sugar can induce neurochemical adaptations (such as altered dopamine and opioid receptor binding) and behavioral hallmarks of dependence (bingeing, withdrawal, and craving). Certainty is graded as low because direct real-time measurements of accumbens dopamine release during sugar consumption rely primarily on animal experimental models (such as rat microdialysis and pig PET imaging) rather than direct human intracerebral measurements.
- supports: Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excess… (Neuroscience and biobehavioral reviews 2008) · cited 1347x in the literature
"Neural adaptations include changes in dopamine and opioid receptor binding, enkephalin mRNA expression and dopamine and acetylcholine release in the nucleus accumbens. The evidence supports the hypothesis that under certain circumstances rats can become sugar dependent." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Sweet preference, sugar addiction and the familial history of alcohol dependence: shared n… (Journal of psychoactive drugs 2010) · cited 94x in the literature
"Moreover, both human and animal studies have demonstrated that in some brains the consumption of sugar-rich foods or drinks primes the release of euphoric endorphins and dopamine within the nucleus accumbens, in a manner similar to some drugs of abuse. The neurobiological pathways of drug and "sugar addiction" involve similar neural receptors, neurotransmitters, and hedonic regions in the brain." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Natural addiction: a behavioral and circuit model based on sugar addiction in rats. (Journal of addiction medicine 2009) · cited 158x in the literature
"Bingeing on a 10% sucrose solution repeatedly releases dopamine in the nucleus accumbens, and it delays the release of acetylcholine, thereby postponing satiety." (abstract, results, passage verified)
pubmedfull study (doi)
Rats sensitized to daily cocaine for seven days retain behavioral sensitization (locomotor frenzy) when challenged with a single dose after a full year of abstinence.
"It's an experiment in rats where rats were injected with cocaine, the same amount of cocaine every day for seven days. And over the course of those seven days, the rats went from kind of hiding in the shadows of the cage to progressively running a little bit more and a little bit more, and by day seven, they were in a running frenzy... Then there was no more cocaine injected after seven days, and no cocaine or any addictive substance administered to the rats for a year... And then the rats were injected with a single dose of cocaine, and immediately they were plunged back into that running frenzy that you saw on day seven." (said at 1:59:20)
No published record matching the claim that rats sensitized to daily cocaine for seven days retain behavioral sensitization (locomotor frenzy) when challenged after a full year of abstinence was located; this does not prove the claim false.
Alcohol acts upon the endogenous opioid system in the brain.
"alcohol also works on our endogenous opioid system, so there's some homology or similarity between alcohol and opioids" (said at 2:00:33)
Extensive preclinical and human evidence demonstrates that alcohol interacts directly and indirectly with the brain's endogenous opioid system. Acute alcohol consumption stimulates the synthesis and release of endogenous opioid peptides (such as beta-endorphin and enkephalins) that act on mu- and delta-opioid receptors within the mesolimbic reward circuitry. This mechanism is further underscored clinically by the efficacy of opioid receptor antagonists (such as naltrexone) in reducing alcohol craving, consumption, and relapse in individuals with alcohol use disorder.
- supports: The life and times of endogenous opioid peptides: Updated understanding of synthesis, spat… (Neuropharmacology 2023) · cited 23x in the literature
"Finally, as a translational example, we discuss the mechanisms of action of naltrexone (NTX), which is used clinically to treat alcohol use disorder. NTX is a synthetic morphine analog that non-specifically antagonizes the action of most endogenous opioid peptides developed in the 1960s and FDA approved in the 1980s." (abstract, passage verified)
pubmedfull study (doi) - supports: Endogenous opioid systems and alcohol addiction. (Psychopharmacology 1997) · cited 766x in the literature
"Among the latter, the endogenous opioids play a key role in the rewarding (addictive) properties of ethanol. Three types of opioid receptors (mu, delta and kappa) represent the respective targets of the major opioid peptides (beta-endorphin, enkephalins and dynorphins, respectively)... Several lines of evidence indicate that alcohol interferes with endogenous opioid mechanisms which are closely linked with dopamine transmission in the mesolimbic pathway." (abstract, passage verified)
pubmedfull study (doi)
At age five, humans have approximately 50% more neuronal connections than they have as adults.
"So essentially, at age five, we have more neurons and neuronal connections than we have in the rest of our adult lives. About 50% more neuronal connections than we'll have as adults, which is what makes us such good learners when we're kids." (said at 2:03:00)
Histological and electron microscopy studies of the developing human cerebral cortex demonstrate that synaptic density and spine counts peak in early childhood at levels approximately 50% (and up to two- to three-fold in certain cortical areas) higher than typical adult baselines. This overproduction of synapses is followed by a prolonged period of synaptic pruning extending through adolescence and early adulthood.
Synaptic pruning and myelination continue through adolescence until approximately age 25 to establish adult neural circuitry.
"But as we age through adolescence to about age 25, we cut back, or what's called prune, the neural circuits that we don't use, and we myelinate, or make more efficient, the neural circuits that we use most often, such that by age 25, we are left with the neurological scaffolding that will serve us for the rest of our adult lives." (said at 2:03:13)
Published neurodevelopmental literature supports the claim that brain maturation—characterized by synaptic pruning of underutilized connections and progressive myelination of active pathways (particularly in the prefrontal cortex and associated associative networks)—continues throughout adolescence into the mid-twenties. Longitudinal and cross-sectional neuroimaging studies show steep developmental trajectories of cortical reorganization and myelination through adolescence that decelerate into young adulthood, establishing the adult structural and functional neural architecture.
Withdrawal from alcohol and benzodiazepines can be life-threatening.
"So we can have life-threatening withdrawal from alcohol and benzodiazepines like Klonopin, Xanax, Ativan." (said at 2:05:38)
Published clinical literature establishes that withdrawal from central nervous system depressants that modulate gamma-aminobutyric acid (GABA) receptors—specifically alcohol and benzodiazepines—can lead to severe, life-threatening autonomic hyperactivity, delirium, and seizures.
Fact-checked episodes
Publications
- Heart transplant outcomes in patients with substance use disorder history: a nationwide cohort study using high-dimensional propensity score matching.European heart journal. Quality of care & clinical outcomes 2026 · CEBM Level 3
- A missed opportunity: a retrospective cohort study of alcohol use disorder pharmacotherapy in hospitalized patients.Alcohol and alcoholism (Oxford, Oxfordshire) 2026 · CEBM Level 3
- The Montreal model of ketamine-therapy for alcohol use disorder and comorbid treatment-resistant depression: protocol for a feasibility trial.BMJ open 2026 · CEBM Level 5
- TikTok is a valuable data source for tracking the opioid crisis.NPJ digital medicine 2026 · CEBM Level 4
- Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study.Journal of addiction medicine 2025 · CEBM Level 3
- Which social media platforms facilitate monitoring the opioid crisis?PLOS digital health 2025 · CEBM Level 4
- Monitoring the opioid epidemic via social media discussions.NPJ digital medicine 2025 · CEBM Level 4
- Predicting treatment retention in medication for opioid use disorder: a machine learning approach using NLP and LLM-derived clinical features.Journal of the American Medical Informatics Association : JAMIA 2025 · CEBM Level 3
- Experiences With Substance Use Disorder Treatment and the Role of Social Norms in the Asian American Pacific Islander Community: A Qualitative Study.Journal of addiction medicine 2025 · CEBM Level 5
- Qualitative exploration of the psychological dimensions of telehealth shared medical appointments (SMAs) for buprenorphine prescribing.Journal of addictive diseases 2024 · CEBM Level 5
- Trends in hallucinogen-associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022.Addiction (Abingdon, England) 2024 · CEBM Level 4
- Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning.Addiction (Abingdon, England) 2024 · CEBM Level 3
- Which social media platforms facilitate monitoring the opioid crisis?medRxiv : the preprint server for health sciences 2024 · CEBM Level 4
- The opioid industry's use of scientific evidence to advance claims about prescription opioid safety and effectiveness.Health affairs scholar 2024 · CEBM Level 5
- A telehealth inpatient addiction consult service is both feasible and effective in reducing readmission rates.Journal of addictive diseases 2023 · CEBM Level 4
- Predicting premature discontinuation of medication for opioid use disorder from electronic medical records.AMIA ... Annual Symposium proceedings. AMIA Symposium 2023 · CEBM Level 3
- Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.Lancet (London, England) 2022 · CEBM Level 5
- Buprenorphine Microdosing Cross Tapers: A Time for Change.International journal of environmental research and public health 2022 · CEBM Level 5
- Gabapentin dependence and withdrawal requiring an 18-month taper in a patient with alcohol use disorder: a case report.Journal of addictive diseases 2021 · CEBM Level 4
- A systematic review of stigma interventions for providers who treat patients with substance use disorders.Journal of substance abuse treatment 2021 · CEBM Level 1
- Patterns of Opioid and Benzodiazepine Use in Opioid-Naïve Patients with Newly Diagnosed Low Back and Lower Extremity Pain.Journal of general internal medicine 2020 · CEBM Level 3
- Tapering Long-Term Opioid Therapy.American family physician 2020 · CEBM Level 5
- Buprenorphine for Long-Term Chronic Pain Management: Still Looking for the Evidence.Annals of internal medicine 2020 · CEBM Level 5
- Online mutual-help intervention for reducing heavy alcohol use.Journal of addictive diseases 2020 · CEBM Level 4
- Unsafe Supply: Why Making Controlled Prescription Drugs Available for Unsupervised Use Will Not Target the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19-- A Commentary on Bonn et al. (2020).Journal of studies on alcohol and drugs 2020 · CEBM Level 5
- Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.Pain medicine (Malden, Mass.) 2019 · CEBM Level 5
- Initiating Opioid Agonist Treatment for Opioid Use Disorder in the Inpatient Setting: A Teachable Moment.JAMA internal medicine 2019 · CEBM Level 5
- Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.Annals of internal medicine 2019 · CEBM Level 5
- Buprenorphine Induction Without Opioid Withdrawal: A Case Series of 15 Opioid-Dependent Inpatients Induced on Buprenorphine Using Microdoses of Transdermal Buprenorphine.American journal of therapeutics 2019 · CEBM Level 4
- Substance Use Among Older Adults: Ethical Issues.Focus (American Psychiatric Publishing) 2019 · CEBM Level 5
- Our Other Prescription Drug Problem.The New England journal of medicine 2018 · CEBM Level 5
- The Opioid Epidemic as a Watershed Moment for Physician Training in Addiction Medicine.Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry 2018 · CEBM Level 5
- Qualitative Assessment of Clerkship Students' Perspectives of the Topics of Pain and Addiction in their Preclinical Curriculum.Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry 2018 · CEBM Level 4
- Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.Anesthesiology clinics 2018 · CEBM Level 5
- Extended treatment for cigarette smoking cessation: a randomized control trial.Addiction (Abingdon, England) 2017 · CEBM Level 2
- Tapering Patients Off of Benzodiazepines.American family physician 2017 · CEBM Level 5
- A call to include people with mental illness and substance use disorders alongside 'regular' smokers in smoking cessation research.Tobacco control 2016 · CEBM Level 5
- Distribution of Opioids by Different Types of Medicare Prescribers.JAMA internal medicine 2016 · CEBM Level 3
- Assessment of provider attitudes toward #naloxone on Twitter.Substance abuse 2016 · CEBM Level 4
- Weighing the Risks and Benefits of Chronic Opioid Therapy.American family physician 2016 · CEBM Level 5
- Retrospective analysis of changing characteristics of treatment-seeking smokers: implications for further reducing smoking prevalence.BMJ open 2016 · CEBM Level 4
- Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification.Journal of substance abuse treatment 2016 · CEBM Level 4
- Use of Opioid Agonist Therapy for Medicare Patients in 2013.JAMA psychiatry 2016 · CEBM Level 4
- A qualitative study of treatment-seeking heroin users in contemporary China.Addiction science & clinical practice 2015 · CEBM Level 4
- Recovery-oriented policy and care systems in the UK and USA.Drug and alcohol review 2014 · CEBM Level 5
- Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol.Journal of psychiatric research 2014 · CEBM Level 4
- Clinical management of alcohol use disorders in the neurology clinic.Handbook of clinical neurology 2014 · CEBM Level 5
- The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.Psychoneuroendocrinology 2013 · CEBM Level 3
- Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression.Psychiatry research 2013 · CEBM Level 4
- Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.Psychological services 2013 · CEBM Level 4
- Why doctors prescribe opioids to known opioid abusers.The New England journal of medicine 2013 · CEBM Level 5
- From self-medication to intoxication: time for a paradigm shift.Addiction (Abingdon, England) 2013 · CEBM Level 5
- Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration.Addiction science & clinical practice 2013 · CEBM Level 3
- Why doctors prescribe opioids to known opioid abusers. How cultural attitudes and financial disincentives affect the prescribing habits of physicians.Minnesota medicine 2013 · CEBM Level 5
- The relationships of positive and negative symptoms with neuropsychological functioning and their ability to predict verbal memory in psychotic major depression.Psychiatry research 2012 · CEBM Level 4
- Time to abandon the self-medication hypothesis in patients with psychiatric disorders.The American journal of drug and alcohol abuse 2012 · CEBM Level 5
- Risk of future trauma based on alcohol screening scores: a two-year prospective cohort study among US veterans.Addiction science & clinical practice 2012 · CEBM Level 3
- Why doctors prescribe opioids to known opioid abusers.The New England journal of medicine 2012 · CEBM Level 5
- Alcohol screening scores and the risk of new-onset gastrointestinal illness or related hospitalization.Journal of general internal medicine 2011 · CEBM Level 3
- Depression and smoking cessation: does the evidence support psychiatric practice?Neuropsychiatric disease and treatment 2007 · CEBM Level 5
- Psychotherapy, symptom outcomes, and role functioning over one year among patients with bipolar disorder.Psychiatric services (Washington, D.C.) 2006 · CEBM Level 3
- Update on augmentation of antidepressant response in resistant depression.Current psychiatry reports 2005 · CEBM Level 5
- A prospective trial of modafinil as an adjunctive treatment of major depression.Journal of clinical psychopharmacology 2004 · CEBM Level 4
- Current status of the utilization of antiepileptic treatments in mood, anxiety and aggression: drugs and devices.Clinical EEG and neuroscience 2004 · CEBM Level 5
- Psychosocial service utilization by patients with bipolar disorders: data from the first 500 participants in the Systematic Treatment Enhancement Program.Journal of psychiatric practice 2004 · CEBM Level 4
- Why is this special issue on women's professional development in psychiatry necessary?Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry 2004 · CEBM Level 5
- Safety of antidepressants in the elderly.Expert opinion on drug safety 2003 · CEBM Level 5
- A Friday in the life of an academic psychiatrist.Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry 2003 · CEBM Level 5
- A Day in the Life of an Academic Psychiatrist.Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry 2003 · CEBM Level 5
- Impaired recognition of facial emotion in mania.The American journal of psychiatry 2002 · CEBM Level 4
- Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders.Bipolar disorders 2002 · CEBM Level 4